Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Chosa

    MCap

    SEK57m

    Last close

    SEK0.80

    ▲ 0.20 (33.33%)

    Vection Technologies

    MCap

    AUD47m

    Last close

    AUD0.04

    ▲ 0.00 (12.90%)

    Metro Bank

    MCap

    GBP684m

    Last close

    GBP1.02

    ▲ 7.90 (8.43%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Avalo: Edison Open House Healthcare 2022

Avalo: Edison Open House Healthcare 2022

Avalo Therapeutics — 1 video in collection

More on this equity

Avalo is a clinical-stage precision medicine company that discovers, develops, and commercializes targeted therapeutics for patients with significant unmet clinical need in the areas of immunology, immuno-oncology and rare disease.

• Tell us about the company.
• How many programmes are you running at the moment?
• Which programmes should investors be focusing on?
• What is the unmet medical need in Crohn’s disease and how is Avalo different in this market?
• How large do you think the Crohn’s market is?
• Tell us about the recent encouraging data on Crohn’s disease.
• Is there a possibility that some people could become refractory to your drug?
• Which milestones should investors focus on in the coming year?
• Please tell us more about your close association with the Children’s Hospital of Philadelphia.

< Previous
Next >

You may also be interested in these:

Healthcare

Recce Pharmaceuticals – executive interview

Healthcare

Making the ordinary, extraordinary: Next generation T cell receptors for precision immunotherapies

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free